Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
SM-030 by DermBiont for Hyperpigmentation: Likelihood of Approval
SM-030 is under clinical development by DermBiont and currently in Phase II for Hyperpigmentation. According to GlobalData, Phase II drugs...